Diabetes: Hormone replacement therapy slashes risk for women

HORMONE replacement therapy slashes the risk of women developing diabetes by more than a third, according to new research today.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 31 July 2018Source: The Lancet Diabetes &EndocrinologyAuthor(s): Wiebke Birnbaum, Louise Marshall, Ralf Werner, Alexandra Kulle, Paul-Martin Holterhus, Katharina Rall, Birgit Köhler, Annette Richter-Unruh, Michaela F Hartmann, Stefan A Wudy, Matthias K Auer, Anke Lux, Siegfried Kropf, Olaf HiortSummaryBackgroundWomen with complete androgen insensitivity syndrome (CAIS) after gonadectomy have complained about reduced psychological wellbeing and sexual satisfaction. The aim of this study was to compare the effectiveness of hormone-replacement therapy with either androgen or oestrog...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: Results from this non-interaction clinical study suggest that Meriva® does not interfere with the antiplatelet activity of the most common antiplatelet agents nor alters the INR values in stable patients assuming warfarin or dabigatran. Similarly, dosages of LT4 or metformin do not need to be adjusted in case of complementary treatment with Meriva®. PMID: 30070343 [PubMed - in process]
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Eur Rev Med Pharmacol Sci Source Type: research
Hormone replacement therapy (HRT) is not associated with cognitive decline when women have recently started the menopause or do not have diabetes, according to US researchers.
Source: Nursing Times - Category: Nursing Source Type: news
Abstract BACKGROUND: Patients with hypopituitarism have an increased mortality. The aim of this study was to investigate comorbidities including cerebral infarction, type 2 diabetes mellitus (T2DM) and malignant tumours in patients with non-functioning pituitary adenomas (NFPA) with and without growth hormone replacement therapy (GHRT). METHOD: Observational cohort study in patients with NFPA within the western region of Sweden. Subjects were identified through the National Patient Registry and followed between 1987-2014. Patient records were reviewed and standardized incidence ratios (SIRs) with 95% confiden...
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Tags: Eur J Endocrinol Source Type: research
Three years after ending hormone replacement therapy for menopause symptoms, women show no significant differences in measures of atherosclerosis versus those who had taken placebo.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Publication date: Available online 17 July 2018Source: The Lancet Diabetes &EndocrinologyAuthor(s): Annewieke W van den Beld, Jean-Marc Kaufman, M Carola Zillikens, Steven W J Lamberts, Josephine M Egan, Aart J van der LelySummaryDuring ageing, the secretory patterns of the hormones produced by the hypothalamic–pituitary axis change, as does the sensitivity of the axis to negative feedback by end hormones. Additionally, glucose homoeostasis tends towards disequilibrium with increasing age. Along with these endocrine alterations, a loss of bone and muscle mass and strength occurs, coupled with an increase in fat m...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Abstract There is increasing evidence that menopause is associated with the progression and severity of non-alcoholic fatty liver disease (NAFLD). Estrogen deficiency worsens non-alcoholic steatohepatitis (NASH) in mice models with fatty liver. The prevalence of NAFLD seems to be higher in postmenopausal compared with premenopausal women. Although more data are needed, lower serum estradiol levels are associated with NASH in postmenopausal women. Apart from estrogen deficiency, relative androgen excess and decrease in sex hormone-binding protein are observed in postmenopausal women. These hormonal changes seem to ...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Publication date: July 2018Source: Multiple Sclerosis and Related Disorders, Volume 23Author(s): Simon B.N. Thompson, Alister Coleman, Nicola WilliamsAbstractYawning is a significant behavioural response and, together with cortisol, is potentially a new diagnostic marker of neurological diseases. Evidence of an association between yawning and cortisol was found which supports the Thompson Cortisol Hypothesis and thermoregulation hypotheses, indication that brain cooling occurs when yawning. 117 volunteers aged 18–69 years were randomly allocated to experimentally controlled conditions to provoke yawning. Thirty-three...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Authors: Ueland GA, Husebye ES Abstract Pharmacological glucocorticoid treatment is associated with adverse metabolic consequences such as hypertension, overweight, reduced glucose tolerance, diabetes mellitus and ultimately increased mortality in cardiovascular disease. Here we review the evidence of detrimental effects of hormone replacement therapy in adrenal insufficiency (AI). Registry studies indicate increased cardiovascular mortality, hypertension, diabetes, and dyslipidemia in both primary and secondary AI, but when cohorts with carefully characterized patients are studied the picture is less clear, and re...
Source: Frontiers of Hormone Research - Category: Endocrinology Tags: Front Horm Res Source Type: research
ConclusionsLower vBMD was associated with increased all-cause mortality in African-American men with T2D, independent of other risk factors for mortality including subclinical atherosclerosis.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Diabetes | Endocrinology | Health | Hormone Replacement Therapy | Hormones | Women